Hydrocodone

Hydrocodone produces dose-dependent suppression of respiratory drive. In patients with severe respiratory depression, acute or severe bronchial asthma in unmonitored settings, or any condition causing significant baseline respiratory compromise, even therapeutic doses may precipitate fatal apnea. This is the single most important absolute contraindication for all full MOR agonists.

Benzodiazepine co-ingestion is one of the most significant risk factors for opioid overdose death. Fields et al. found synergistic CNS toxicity at lower drug concentrations than expected for either drug alone. Benzodiazepine-related deaths increased 5-fold from 1999–2009, largely driven by opioid co-ingestion (Jann et al. 2014). FDA black-box warning mandates caution. Note: this interaction was absent from the seed data interaction list despite being a primary cause of opioid overdose mortality.

In patients with head injury, intracranial lesions, or elevated ICP, hydrocodone may further elevate CSF pressure and produce clinical signs (miosis, sedation, respiratory depression) that obscure neurological monitoring. Use requires careful risk-benefit assessment and close monitoring.

Concurrent use of MAOIs or use within 14 days of discontinuation is contraindicated due to the risk of serotonergic crisis and unpredictable potentiation of opioid effects. The specific mechanism for hydrocodone is not fully elucidated, but class-level evidence supports this contraindication.

Hepatic impairment alters the two primary CYP-mediated metabolic pathways (CYP3A4 → norhydrocodone; CYP2D6 → hydromorphone). The resulting change in metabolite ratios is unpredictable, potentially increasing hydromorphone formation (increased effect) or decreasing overall clearance (accumulation). Dose reduction and extended monitoring intervals are warranted.

In patients with severe renal impairment, reduced clearance of hydrocodone and its pharmacologically active metabolite hydromorphone may produce accumulation with unpredictable potentiation of opioid effects, including delayed-onset respiratory depression. Dose reduction and extended dosing intervals are recommended.

CYP2D6 ultra-rapid metabolizers convert hydrocodone to hydromorphone (MOR Ki ~0.6 nM, 33-fold higher affinity) at accelerated rates. Standard doses may produce supratherapeutic opioid effects, including excessive respiratory depression, sedation, and euphoria. Pharmacogenomic testing identifies this phenotype. Dose reduction or alternative opioid selection is recommended.

Patients with documented hypersensitivity or anaphylactic reaction to hydrocodone or other morphinan opioids should not receive hydrocodone. Cross-reactivity within the morphinan class is possible.

Hydrocodone crosses the placenta. Chronic in-utero exposure is associated with neonatal opioid withdrawal syndrome (NOWS), presenting as irritability, tremor, feeding difficulties, and respiratory distress in the neonate. Shendre et al. identified significant pharmacotherapy research gaps for opioids in maternal populations. Use during pregnancy requires careful risk-benefit assessment with obstetric and neonatal specialist involvement.

Hydrocodone, like other MOR agonists, increases tone in the sphincter of Oddi. In patients with biliary tract disease, cholecystitis, or acute pancreatitis, this may exacerbate pain and obstruction. Alternative analgesic strategies should be considered.

Paralytic ileus, Known or suspected gastrointestinal obstruction

All opioid class agents are contraindicated in known or suspected gastrointestinal obstruction and paralytic ileus. Hydrocodone further reduces GI motility via peripheral MOR activation, potentially converting partial obstruction to complete obstruction or worsening ileus.